{
  "abstract": "Over the past decade, the incidence of colorectal cancer (CRC) has continued to rise, imposing a substantial disease burden on both patients and society. Improvements in treatment strategies—including surgery, chemotherapy, targeted therapy, and immunotherapy—have significantly improved clinical outcomes. Immunotherapy, particularly immune checkpoint inhibitors, has shown promising efficacy in rectal cancer studies. Nevertheless, multiple CRC subtypes are still hindered by an immunosuppressive tumor microenvironment, the development of therapeutic resistance, and low response rates to immunotherapy, collectively limiting further gains in clinical benefit. As an emerging therapeutic modality, bispecific antibodies (BsAbs) possess two binding specificities, enabling them to bind simultaneously to the same or different antigens, thereby generating multifaceted anti-tumor effects. Therefore, BsAbs can help overcome treatment resistance and potentiate antitumor immune responses. To date, numerous BsAbs have been used in clinical trials to assess their safety and efficacy across diverse CRC subtypes. This review summarizes the main classes of BsAbs used for CRC treatment, focusing on their mechanisms of action and recent advances in clinical research. We further discuss existing challenges for BsAbs and the potential strategies.",
  "abstract_shown": true,
  "affiliations": [
    "Department of Health Management Center & Institute of Health Management, Sichuan Provincial People’s Hospital, School of Medicine, University of Electronic Science and Technology of China",
    "Department of Respiratory and Critical Care Medicine, West China Hospital, Sichuan University/West China School of Nursing, Sichuan University",
    "Department of Thyroid Surgery, Sichuan Provincial People’s Hospital, University of Electronic Science and Technology of China",
    "Department of Chinese Medicine, Sichuan Provincial People’s Hospital, School of Medicine, University of Electronic Science and Technology of China"
  ],
  "article_type": null,
  "arxiv": null,
  "author_total": 4,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "Kai Long"
    },
    {
      "affs": [
        1
      ],
      "name": "Yihua Zeng"
    },
    {
      "affs": [
        2
      ],
      "name": "Chao Chen"
    },
    {
      "affs": [
        3
      ],
      "name": "Qipeng Yao"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/dq7rwqwqv3px4.bib",
  "cited_by": 0,
  "doi": "10.3389/fimmu.2026.1995473",
  "fulltext_url": null,
  "id": "dq7rwqwqv3px4",
  "issns": [
    "1664-3224"
  ],
  "landing_url": "https://www.frontiersin.org/articles/10.3389/fimmu.2026.1995473/full",
  "language": null,
  "licence": "CC-BY-4.0",
  "licence_label": "CC BY 4.0",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by/4.0/",
  "metadata_licence": null,
  "native_subjects": [],
  "openalex": null,
  "pdf_url": null,
  "pmcid": null,
  "pmid": null,
  "published": "2026-11-12",
  "publisher": "Frontiers Media SA",
  "ris": "https://research.draconitic.com/paper/dq7rwqwqv3px4.ris",
  "sources": [
    {
      "first_seen": "2026-11-12T12:22:47Z",
      "native_id": "10.3389/fimmu.2026.1995473",
      "source": "crossref",
      "url": "https://www.frontiersin.org/articles/10.3389/fimmu.2026.1995473/full"
    }
  ],
  "subjects": [
    {
      "field": "biology",
      "origin": "issn:1664-3224",
      "subfield": "immunology"
    }
  ],
  "title": "Application and future prospects of bispecific antibodies in the treatment of colorectal cancer",
  "title_text": "Application and future prospects of bispecific antibodies in the treatment of colorectal cancer",
  "type": "peer-reviewed",
  "updated_at": "2026-11-14T00:20:56Z",
  "url": "https://research.draconitic.com/paper/dq7rwqwqv3px4",
  "venue": "Frontiers in Immunology",
  "versions": []
}